-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
API China: Shijiazhuang Sihua Pharmaceutical Group Highlights Its Strong Brands in Active Pharmaceutical Ingredients and Pharmaceutical Packaging Materials
Category:
发布时间：2024-10-23
【概要描述】
In the golden autumn, Xi’an’s Chanba District gleams with rippling waters and the sweet fragrance of osmanthus, warmly welcoming domestic and international guests attending API China. On October 16, the 91st China International API, Intermediates, Packaging, and Equipment Fair (API China) was grandly held at the Xi’an International Convention and Exhibition Center. Hebei Guangxiang Pharmaceutical Co., Ltd., Hebei Guolong Pharmaceutical Co., Ltd., and Jiangsu Bosheng Medical New Materials Co., Ltd.—all subsidiaries of Shijiazhuang Sihua Pharmaceutical Group—made a collective appearance at the event, showcasing their latest innovative achievements.
In the golden autumn of Xi’an’s Chanba District, shimmering waters and the sweet fragrance of osmanthus greet domestic and international guests attending API China. On October 16, the 91st China International API, Intermediates, Packaging, and Equipment Exhibition (API China) was grandly held at the Xi’an International Convention and Exhibition Center. Hebei Guangxiang Pharmaceutical Co., Ltd., Hebei Guolong Pharmaceutical Co., Ltd., and Jiangsu Bosheng Medical New Materials Co., Ltd.—all subsidiaries of Shijiazhuang Sihua Pharmaceutical Group—made a collective appearance at the event, showcasing their latest innovative achievements.
According to reports, as the premier industry event in China’s pharmaceutical manufacturing sector, API China brings together more than 1,000 companies specializing in active pharmaceutical ingredients, intermediates, pharmaceutical excipients, pharmaceutical packaging, pharmaceutical equipment, R&D outsourcing, contract manufacturing, and biopharmaceutical supply-chain solutions. In collaboration with over 5,000 pharmaceutical manufacturers nationwide and nearly 30,000 professionals from the pharmaceutical industry, API China is fostering innovative partnerships to unlock new opportunities for growth. By leveraging innovation to drive industrial upgrading, the event aims to establish new competitive advantages for China’s pharmaceutical industry and, together with its peers, build a resilient, secure, and ever-expanding value chain.
At the exhibition, the Group’s custom-designed booth, rendered in a sophisticated blue-and-white color scheme, exuded an air of elegance and gravitas. The backdrop panel showcased a comprehensive catalog of 64 active pharmaceutical ingredients and other products, vividly highlighting the Group’s rich and diversified innovation achievements in API and pharmaceutical packaging material R&D over recent years. A thoughtfully crafted lightbox display centrally featured an impressive array of products alongside digital, intelligent, and sustainable manufacturing scenarios. These included key APIs renowned for their high quality and strong market reputation—such as caffeine, azithromycin, and metronidazole—as well as a wide range of specialty APIs like epalrestat, betahistine mesylate, argatroban, and the adrenaline series, along with BoSheng Medical’s non-PVC infusion film and coated rubber stoppers, among other pharmaceutical packaging materials.
The integrated development of “active pharmaceutical ingredients plus finished dosage forms” has not only effectively propelled the company’s high-quality growth but also strengthened the Group’s brand presence in the pharmaceutical market. On the morning of the first day of the exhibition, the Group’s booth was bustling with visitors, the negotiation area was packed, and our sales team was hard at work, fielding inquiries from domestic and international clients, engaging in in-depth discussions on current business collaborations as well as plans for 2025, and striving to achieve mutually beneficial outcomes for both parties.
In recent years, Shijiazhuang Sihua Pharmaceutical Group has been driven by innovation, aligned with national strategic development priorities, and actively pursued an integrated “API–formulation” business strategy. The company has strategically linked its innovation efforts to the industrial value chain, while intensifying R&D on high-end, complex generic drugs and innovative pharmaceuticals. At the same time, in response to domestic and international market demands, it has proactively developed specialty API products and secured international certifications for these products. Currently, the proportion of specialty APIs among the group’s pipeline of new products is steadily increasing; to date, 64 such products have received regulatory approval, and their commercialization is accelerating, making this a new highlight of the company’s innovative growth.
“Innovation drives transformation, optimizes structure, and elevates capability, enabling breakthroughs beyond traditional boundaries and accelerating the extension of the API innovation value chain toward the mid- to high-end segments,” said a spokesperson for the group. The group noted that R&D innovation in APIs and the commercialization of research outcomes are gaining momentum, leading to improved quality and efficiency; the portfolio of signature, competitive products is steadily expanding; the company has become an affiliated supplier to numerous domestic formulation manufacturers; and its brand influence within the industry is increasingly prominent.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091